Enfortumab vedotin for Urothelial Carcinoma User Reviews
Brand names: Padcev
Enfortumab vedotin has an average rating of 3.0 out of 10 from a total of 3 reviews for the treatment of Urothelial Carcinoma. 0% of reviewers reported a positive experience, while 67% reported a negative experience.
- DMa...
- April 16, 2021
Padcev (enfortumab vedotin) "My son was diagnosed with Stage 4 bladder cancer in Oct/2019. His treatment consisted of surgery, radiation, chemotherapy, Keytruda, before being treated with Padcev. The side effects from his first dose of Padcev were much like his previous treatment of chemotherapy back in Dec/2019-Feb/2020. He was tired, nauseous, and lost his appetite. After his second dose, he immediately lost his hair, he was nauseous, lost his appetite, and had diarrhea. But the most frightening side effect was he developed a rash that was ugly, red, and blistery. A week later, based on the results of a blood test, he was called and told to go to the ER for what we thought was either iron or a blood transfusion, but after getting there, the ER doctor told us that he was in renal failure and would have to stay in the hospital until they found the cause of it and were able to treat it. They were never able to get his kidneys working again. He ended up passing away 5 days after he was admitted to the hospital."
- Anonymous
- Taken for 1 to 6 months
- September 26, 2021
"I have had very little side effects due to this medication, mostly Transient. The most annoying thing is numbness in the fingers loss of taste and smell general muscle pain."
More about enfortumab vedotin
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Padcev (enfortumab vedotin) "Severe reaction to the medication Padcev. Suffering blisters all over my body that bleed profusely. No one has answered questions about how long the medication remains in the system after discontinued."